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Fluorescence Resonance Energy Transfer (FRET) is an approach widely used to detect 
protein-protein interactions in live cells. This approach is based on the sensitization of an 
“acceptor” molecule by the energy transfer from a “donor” when there is an overlap between 
the emission spectrum of the “donor” and the excitation spectrum of the “acceptor” and close 
proximity between the two fluorophore species (in the region of 8 nm). Various methods 
exist to quantify FRET signals: here we describe the application of homogeneous time-
resolved FRET (htrFRET) combined with Tag-liteTM technology and its application to 
determine not only protein-protein interactions but also the capability of GPCR mutant 




G protein-coupled receptors (GPCRs) are a vast class of trans-plasma membrane proteins that 
play pivotal roles in cell signalling and in the regulation of a broad range of biological 
processes. Dysregulation of many of these result in serious pathological conditions and, as 
such, GPCRs represent a major target class for therapeutic drug development (1). 
GPCRs have been classically described as monomeric units that bind in a stoichiometric 1:1 
ratio to both ligand and downstream signalling proteins such as members of the family of 
heterotrimeric guanine nucleotide binding proteins (G-proteins). Indeed, studies in which 
monomeric GPCRs were incorporated into nanodiscs demonstrated that each of the ² 2-
adrenoceptor, rhodopsin, and the µ-opioid receptor can function effectively as monomers (2, 
3, 4, 5). However, in recent years a growing number of studies have supported the hypothesis 
that GPCRs may also exist as dimeric or oligomeric complexes (6, 7). In the case of various 
members of the class C, metabotropic glutamate receptor family it is clear that formation of 
either homo- or hetero-complexes define the pharmacology and function of the receptor (7). 
However, in the case of the more numerous class A, rhodopsin-like receptors, the situation is 
more uncertain and both the basic concept of GPCR oligomerization and its functional 
relevance remain controversial topics (6). 
The first structural evidence supporting organization of a class A GPCR into 
dimers/oligomers was provided by the application of atomic force microscopy to murine rod 
outer segment discs that indicated that rhodopsin is arranged as a series of parallel arrays of 
dimers (8). Since 2007 innovative crystallographic techniques have resulted in rapid growth 
in the number of available atomic level GPCR structures (9). Such structures are consistent 
with, for example, the µ-opioid and the ² 1-adrenoceptor, being able to organize as parallel 
dimers and/or tetramers, and suggest the existence of multiple dimer interfaces in different 
GPCR homodimers. Transmembrane domain (TMD) V and TMD VI residues provide the 
main interface for µ-opioid receptor dimers while TMD I, TMD II and helix 8 residues 
generate a second, more limited, interface (10). A TMD I–TMD II–helix 8 interface (with 
slightly different contact residues) was also found in crystals of the turkey ² 1-adrenoceptor 
(11) where it constitutes the most prominent interaction interface. An additional interface 
involving TMD IV and TMD V residues was also observed for this receptor (11). 
Both biochemical and biophysical approaches have been employed to study the basis of 
GPCRs dimerization/oligomerization (12). However, traditional biochemical techniques such 
as immunoblotting, cross-linking and co-immunoprecipitation, have clear limitations in 
efforts to study interactions involving integral membrane proteins owing to the need to use 
non-physiological buffers and detergents that may cause aggreration or disruption of native 
biological interactions. 
In the past decade, several biophysical methods based on Resonance Energy Transfer (RET) 
between two molecules, known as the “donor” and “acceptor”, have been developed to 
examine the quaternary organization of integral membrane proteins, including GPCRs, in 
intact cells. These include both Bioluminesence Resonance Energy Transfer (BRET) and 
Fluorescence Resonance Energy Transfer (FRET). Moreover, when combined with protein 
complementation assays that allow the reconstitution of a fluorophore from two non-
fluorescent polypeptides that are brought into proximity by interactions between the proteins 
they are attached to, larger scale complexes can, at least potentially, be detected and imaged. 
Although these techniques overcome a number of the issues with the biochemical approaches 
noted above, they both generally require genetic manipulation of the proteins, thus limiting in 
vivo analysis without a committed effort to generate transgenic organisms and report 
proximity between proteins rather than association per se. 
In this chapter we describe the application of homogenous time-resolved FRET (htrFRET) 
using SNAP-Tag-liteTM technology combined with alanine scanning mutagenesis to 
characterize and quantify oligomerization of GPCRs and mutant variants of interest at the 
surface of suitably transfected and engineered cells. The procedure involves the generation of 
a construct in which the GPCR of interest is linked to the SNAP-tag (13, 14, 15), in such a 
way that the SNAP-tag is located on the extracellular face of the plasma membrane when the 
GPCR is correctly expressed and displayed. Subsequently incubation of the cells with a 
combination of an appropriate energy “donor” and ”acceptor” pair allows detection of energy 
transfer between the two fluorophores if the protein forms a homo-oligomeric complex 
(Figure 1).  
The SNAP-tag is a modified version of the DNA repair protein O6-alkylguanine-DNA 
alkyltransferase (AGT) that displays faster reaction kinetics with O6-benzylguanine (BG) 
substrates and no longer interacts with DNA. BG substrates can be conjugated with 
fluorophores including Europium cryptate (or a Terbium cryptate), which can act as long-
lived fluorescence energy donors, as well as molecules such as the Cy5-like dye (d2), which 
can act a suitable energy “acceptor” in a FRET assay (13). Due to the particular properties of 
such rare-earth cryptates, which generate fluorescence emission with lifetime in the 
millisecond range, compared to the nanosecond range for standard fluorophores, it is possible 
to record the FRET signal between donor to acceptor in a ‘time resolved’ manner (htrFRET). 
Suitable time gating of the signal allows autofluorescence to rapidly decay, producing a 
decrease in background signal. Moreover, a further consequence of the properties of the 
selected fluorophores is that they produce a large increase in the signal to noise ratio when 
compared to classical FRET methods (13). 
 
2. Materials 
2.1. Molecular biology 
1. Mammalian expression plasmid containing the cDNA sequence coding for the SNAP-tag 
modified-GPCR of interest (such as PSEM1-26 m plasmid supplied by Covalys Biosciences 
AG/New England Biolabs). 
2. Mammalian expression plasmid not containing the cDNA sequence coding for the GPCR 
of interest to use as a negative control in htrFRET assay. 
3. Enzymes suitable for cloning (such as restriction enzymes and DNA ligase)  
4. Primers . 
5. Pfu DNA polymerase .6. dNTP mix, 10 mM each .7. DpnI. 
8. XL1-Blue competent cells. 
9. Luria-Bertani (LB) Broth  dissolved in distilled water according to the manufacture’s 
protocol. Autoclave at 121°C, 15 min and store at room temperature. 
10. LB-agar plates: dissolve LB-agar  in distilled water according to the manufacture’s 
protocol. Autoclave at 121°C, 15 min, allow to cool to 55°C and add the appropriate amount 
of the desired antibiotic for selection. Pour LB-agar into Petri dishes and allow to set. Invert 
the plates and store at 4°C. 
11. Miniprep kit. 
2.2. Cell Culture  
1. Suitable cells for transfection (e.g. Human Embryonic Kidney 293 cells, HEK293T cells). 
2. Suitable growth medium, such as Dulbecco´s Modified Eagle´s medium containing 0.292 
g/L L-glutamine, 1% penicillin/streptomycin mixture  and 10% heat-inactivated fetal bovine 
serum.  
3. Cell culture dishes 60 mm x 15 mm style. 
4. Transfection reagent such as polyethylenimine (PEI). 
5. Sodium chloride: 150mM NaCl. Autoclave at 121°C, 15 min and store at room 
temperature. 
6. Poly-D-lysine: 0.1mM poly-D-lysine dissolved in sterile tissue culture grade water. Store 
at 4°C. 
7. Trypsin. 
2.3. HtrFRET assay 
1. Dimethyl sulfoxide (DMSO). 
2. Phosphate buffered saline (PBS, 10X): 1370mM NaCl, 27mM KCl, 100mM Na2HPO4, 
20mM KH2PO4 dissolved in distilled water. Store at room temperature. To obtain the 
working solution, PBS 1X, dilute PBS 10X in distilled water in a ratio 1:9 and assess the pH 
of the solution that must be 7.4. 
 
3. Black 96 well plate (Greiner Bio-One). 
4. SNAP-Lumi4Tb (Cisbio). 
5. SNAP-Red (Cisbio). 
6. Labeling medium 5X (Cisbio). 
2.4 Equipment 
1. Standard cell culture facility including biological safety cabinet and 37°C incubator with 
5% CO2. 
2. Thermal cycler. 
3. Microplate reader (such as Pherastar BMG Labtech). 
4. GraphPad Prism 5.2 software for data analysis. 
3. Methods 
3.1. Preparation of expression plasmids 
1. Modify PSEM1-26 m plasmid, containing the SNAP-tag coding sequence by the addition 
of a small linker region encoding the metabotropic glutamate receptor 5 signal sequence 
(MVLLLILSVLLLKEDVRGSAQS) between the Cla1 and EcoR1 sites of the multiple 
cloning site and upstream of the SNAP-tag (MCS1). PCR amplify the cDNA coding the 
GPCR of interest using primers designed to add BamH1 and Not1 consensus sequences to the 
fragment termini and then ligate into the multiple cloning site downstream of the SNAP-tag 
(MCS2) of the modified plasmid.  
3.2. Generation of GPCR mutant variants by alanine substitution mutagenesis 
1. Design mutagenic primers: both the forward and the reverse primers must contain the 
desired mutation (preferably in the centre of the sequence) and anneal to the same sequence 
on opposite strands of the plasmid. Primers should have a minimum GC content of 40%, be 
between 25 and 45 bases in length, with a melting temperature (Tm) of e78°C and terminate 
in one or more C's or G's.  
2. Generate the SNAP-tag-GPCR mutant variants using a modification of the QuikChange 
method (Stratagene, Agilent Technologies, Santa Clara, CA). To amplify the SNAP-tag-
GPCR construct and introduce the desired mutation combine in a sterile nuclease-free 
microcentrifuge tube the PCR reaction components in a total volume of 50 µL (Table 1). 
Prepare also a PCR control reaction without including the Pfu DNA polymerase. 
3. Place the PCR reactions in a thermal cycler and after the initial denaturation step at 95°C 
for 1 min start the 18-20 cycles program consisting of denaturation at 95°C for 1 min, primer 
annealing at 55°C for 1 min and DNA synthesis at 72°C for 2 min for every 1 kb DNA to be 
amplified. Final DNA extension at 72°C for 10 min and after that the tube is maintained at 
4°C (see Note 1). 
4. Add 1 µL (equivalent to 10 U) of DpnI to the PCR reaction tube to digest the methylated 
non-mutated DNA and incubate at 37°C for at least 60 min. 
5. Add 1-10 µL of the digest reaction to 50 µL of XL1-Blue competent cells, incubate 15 min 
on ice, heat-shock at 42°C for 90 sec and then incubate 2 min on ice. Add 450 µL of LB-
Broth and incubate with shaking at 37°C for 60 min. Spread the cell suspension on LB-agar 
plates containing the correct antibiotic for selection and incubate overnight at 37°C. 
6. Select 3 colonies randomly and grow them overnight in 5 mL LB-Broth. The next day 
isolate the plasmids using miniprep kit (follow manufacturer`s protocol) (see Note 2). 
7. Check the presence of mutation in the isolated plasmids by sequencing. 
3.3. Transient expression in mammalian cells 
1. Plate mammalian cells onto 60 mm cell culture dishes and grow to 70-80% confluency 
overnight at 37 °C with 5% CO2. 
2. Transfect the cells with the plasmid of interest following the PEI protocol (16). Combine 
the DNA with PEI (ratio 1:6) in 250 µL of 150 mM NaCl solution. Mix thoroughly the DNA-
PEI mixture and incubate for 10 min at room temperature. Change medium to the cell plates 
and add the DNA-PEI mixture to the cell medium in a drop-wise manner. The following 
transfections are needed: 
a. Empty plasmid not containing the GPCR of interest (see Note 3). 
b. Expression plasmid containing the GPCR of interest (wild type or mutant variant of the 
GPCR). 
3.4. Optimization of htrFRET conditions and determination of the cell surface GPCR 
oligomeric interaction 
1. Trasfect HEK293T cells with 2 µg of plasmid containing the SNAP-GPCR construct of 
interest (for details see step 2 in section 3.3) (see Note 3). This step is performed in day 1. 
2. Plate 30000 cells per well (100 µL per well) onto black 96 well plates previously pre-
treated with poly-D-lysine and incubate overnight at 37 °C with 5% CO2 (see Note 4). This 
step is performed in day 2. 
3. Prepare labeling medium 1X solution diluting the labeling medium 5X with distilled water 
in a ratio1:4 and keep the solution at room temperature. This step is performed in day 3 
4. Reconstitute 5nmol SNAP-Lumi4Tb adding 50 µL of DMSO to get a 100 µM SNAP-
Lumi4Tb stock solution, make 5 µL aliquots and store at -80°C. To obtain the 10 µM SNAP-
Lumi4Tb working solution dilute SNAP-Lumi4Tb stock solution with DMSO in 1:9 ratio 
(see Note 5). This step is performed in day 3. 
5. Reconstitute 20nmol SNAP-Red adding 200 µL of DMSO to get a 100 µM SNAP-Red 
working solution, make 5 µL aliquots and store at -80°C (see Note 5). This step is performed 
in day 3. 
6. Prepare different solutions with a fixed concentration (10nM) of the energy donor SNAP-
Lumi4Tb and different concentrations of the energy acceptor SNAP-Red (0-1000 nM) in 
labeling medium 1X. (see Note 5). This step is performed in day 3. 
7. Aspirate the cell growth medium and replace it, adding to each well 50 µL of one of each 
solution made in the step 4 (see Note 5). This step is performed in day 3. 
8. Incubate the plates for 1 h at 37°C in a humidified atmosphere (5% CO2), (see Note 4). 
This step is performed in day 3. 
9. Aspirate the SNAP-Lumi4Tb and SNAP-Red containing medium and wash the plate 4 
times with 100 µL PBS 1X. This step is performed in day 3. 
10. Add 100 µL of labeling medium 1X. This step is performed in day 3. 
11. Measure the fluorescence emission using a microplate reader (Pherastar). Excite the 
donor SNAP-Lumi4Tb with light of wavelength 337 nm and detect simultaneously the 
emission light of donor SNAP-Lumi4Tb at 620 nm and the emission light of acceptor SNAP-
Red at 665 nm. This step is performed in day 3. 
12. Analyse the data using GraphPad Prism 5.2 (or similar). Plot the htrFRET signal at 665 
nm on the Y axis and the logarithm of molar concentration of SNAP-Red on the X axis and 
apply the Gaussian equation of the nonlinear regression curve fit analysis (Figure 2) 3.5. 
Studying the effect of mutation of the GPCR on oligomeric organization  
1. Transfect HEK293T cells with increasing amounts of plasmid containing SNAP-GPCR 
wild type or SNAP-GPCR mutant variant (of interest) sequence (for details see step 2 in 
section 3.3) (see Note 3). This step is performed in day 1. 
2. Plate 30000 cells/well (100 µL per well) from each transfection plate onto black 96 well 
plates and incubate overnight at 37°C with 5% CO2 (see Note 4). This step is performed in 
day 2. 
3. Prepare a solution in labeling medium 1X containing a fixed concentration (10 nM) of 
energy donor SNAP-Lumi4Tb and a concentration of energy acceptor SNAP-Red as 
determined in section 3.4. (see Note 5). This step is performed in day 3. 
4. Incubate for 1 h at 37°C in a humidified atmosphere (5% CO2) (see Note 5). This step is 
performed in day 3. 
5. Aspirate the SNAP-Lumi4Tb and SNAP-Red mixture and wash the plate 4 times with 100 
µL PBS 1X. This step is performed in day 3. 
6. Add 100 µL of labeling medium 1X. This step is performed in day 3. 
7. Measure the fluorescence emission using a microplate reader (Pherastar) as described in 
step 11 section 3.4. This step is performed in day 3. 
8. Analyse the data using GraphPad Prism 5.2 (or similar) software, plot the fluorescence 
emission at 620 nm on the X axis and the htrFRET signal at 665 nm on the Y axis and apply 
linear regression curve fit analysis to each dataset (Figure 3). 4. Notes 
1. The PCR conditions for the synthesis of the mutant constructs are based on the annealing 
temperature of the primers and may require some modifications of the conditions described 
here. If the reaction fails, sometimes lowering the primer concentration, increasing the 
template concentration, or decreasing the annealing temperature can help. 
2. If after transformation of the competent cells with the PCR reaction no (or very few) 
colonies are observed then increase the volume of the PCR reaction used in the 
transformation protocol.  
3. Always perform the htrFRET assay by including cells transfected with an empty vector to 
establish the background signal. 
4. Perform the htrFRET assays in triplicate. 
5. In the htrFRET assay always protect the energy donor and the energy acceptor 
fluorophores from external light. 
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Figure legends 
Figure 1. Schematic representation of the procedure described in this book chapter. The 
procedure involves (1) the generation of the plasmid constructs containing the sequence 
coding for the SNAP-GPCR of interest or the receptor mutant variant generated by site direct 
mutagenesis, (2) the expression of those constructs in a suitable mammalian cell system and 
(3) the seeding of 30000 cells per well of a 96 well plate. Following an htrFRET assay that 
requires (4) incubation of the cells with a combination of energy “donor” and “acceptor”, and 
(5) detection of the signal at 620 nm and 665 nm after excitation at 337 nm (6) the data are 
analysed 
 
Figure 2. Cell surface oligomeric interactions of VSV-SNAP-hM3R were defined by 
htrFRET. Optimal concentrations of the SNAP-tag htrFRET energy donor and acceptor were 
established by incubating cells with a fixed concentration of energy donor (SNAP-Lumi4Tb, 
10 nM) and various energy acceptor (SNAP-Red) concentrations. htrFRET measured at 665 
nm after excitation at 337 nm reflects proximity between labelled copies of VSV-SNAP-
hM3R at the cell surface. At low energy acceptor concentrations the htrFRET signal is low 
and this increases with increasing SNAP-Red concentration, reaching a maximum that 
represent the optimum ratio of energy donor and acceptor (10 and 100 nM, respectively in 
this example shown) to detect cell surface oligomers. Further increases of SNAP-Red 
concentration results in a decrease in htrFRET signal due to the binding competition of 
SNAP-Lumi4Tb and SNAP-Red for the same tag on the GPCR construct. 
 
Figure 3. HEK293T cells were transfected with increasing amounts (0-2.5 µg of plasmid) of 
either VSV-SNAP-hM3R (circles) or of a mutant receptor variant Leu80Ala, Ile83Ala, 
Ile84Ala, Ile87Ala VSV-SNAP-hM3R (triangles) containing four point mutations in which 
each of residues Leu80, Ile83, Ile84, and Ile87 in TMD I were substituted by alanines, for 24 
h and then incubated with the optimal combination and ratio of SNAP-Lumi4Tb (10 nM) and 
SNAP-Red (100 nM) as estimated insection 3.4. The htrFRET signal determined as 
fluorescent emission at 665 nm was then plotted as a function of cell surface SNAP-tagged 
receptor expression measured by fluorescent emission at 620 nm. A linear dependence 
between the fluorescence emission at 620 nm and the htrFRET signal at 665 nm  is observed 
in both forms of the receptor. The lower extension of the line for Leu80Ala, Ile83Ala, 
Ile84Ala, Ile87Ala VSV-SNAP-hM3R demonstrates that this variant was less effectively 
delivered to the cell surface than the wild type receptor whilst the reduction in the slope of 
the line 665nm/620 nm for this mutant indicates an alteration in oligomeric organization 
consistent with the energy acceptor and donor species being further apart in this variant. The 
illustration above the data section of the Figure records the amino acid sequence of TMD I of 
hM3R. Amino acids in bold are those mutated in Leu80Ala, Ile83Ala, Ile84Ala, Ile87Ala 
VSV-SNAP-hM3R. The most conserved residue (N) in TMD I across the entire family of 
class A GPCRs is denoted as residue 1:50 using the Ballesteros and Weinstein equivalent 
residue positioning system (17). 
 
Tables 
Table 1. PCR reaction components 
Pfu DNA polymerase 10x buffer with Mg2SO4 5 µL 
dNTP mix, 10 mM each 1 µL 
Forward primer 5-50 pmol 
Reverse primer 5-50 pmol 
DNA template <0.5 µg 
Pfu DNA polymerase (2-3 U/µl) 1.25 U 
Nuclease-free water to a final volume of 50 µL 
 
 
